NCT06454344 The Iowa ACEs and Sleep Cohort and Manipulating Sleep in Young Adults With ACEs Studies

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 70 participants in total. It began in 2024-05-01 with a primary completion date of 2027-12-15.

Brief Summary

The overall purpose of this study is to understand the role of disrupted sleep in the association of exposure to early life adversity (adverse childhood experiences (ACEs)) with vascular endothelial (dys)function. In Aim 1 (The Iowa ACEs and Sleep Cohort Study), the investigators will utilize a cross-sectional cohort design with a state-of-the-art translational approach. Participants will be recruited to objectively characterize the degree to which lower sleep quality and quantity contribute to ACEs-related endothelial dysfunction, inflammation, and oxidative stress in young adults using: 1. rigorous at home sleep monitoring using 7-nights of wrist actigraphy and 2 nights of home-based polysomnography to objectively measure sleep quality (sleep efficiency, wakefulness after sleep onset and sleep depth), and total sleep duration, 2. in vivo assessment of endothelial function via flow-mediated dilation testing, and 3. in vitro determination of endothelial cell inflammation and oxidative stress from biopsied endothelial cells. This study to achieve this Aim. In Aim 2, approximately 70 eligible participants from Aim 1 (The Iowa ACEs and Sleep Cohort Study) will then be randomized to either a 6-week behavioral sleep intervention (cognitive behavioral therapy for insomnia) or a wait-list control to determine the mechanistic contribution of sleep disruption to vascular dysfunction in young adults with moderate-to-high exposure to adverse childhood experiences (ACEs). Following the intervention, participants will again complete: 1. rigorous at home sleep monitoring using 7-nights of wrist actigraphy and 2 nights of home-based polysomnography to objectively measure sleep quality (sleep efficiency, wakefulness after sleep onset and sleep depth), and total sleep duration, 2. in vivo assessment of endothelial function via flow-mediated dilation testing, and 3. in vitro determination of endothelial cell inflammation and oxidative stress from biopsied endothelial cells.

Eligibility Criteria

AIM 1 Inclusion Criteria: 1. 18-29 years of age 2. SBP \<129 and DBP \<90 mmHg 3. Body Mass Index \> 18.5 kg/m2 and \<35 kg/m2 4. Willing to complete in-home sleep studies Exclusion Criteria: 1. Currently undergoing treatment for a sleep disorder or diagnosed with restless leg syndrome, hypersomnia, parasomnia or narcolepsy, or obstructive sleep apnea 2. Currently performing overnight shift work 3. Lifetime history of any psychiatric disorder with psychotic features or bipolar disorder, currently undergoing treatment for substance-induced mood disorder 4. Endorsed suicidal ideation as indicated by a Moderate or High risk determination on the Columbia Suicide Risk Protocol 5. Diagnosed neurological disorder or illness affecting the central nervous system 6. Diagnosed acute or chronic autoimmune disease or chronic inflammatory condition 7. Current or previous cancer diagnosis 8. History of moderate or severe traumatic brain injury 9. Current or previous history of CBT-I treatment or sleep restriction or cognitive restructuring therapy for sleep 10. History of cardiometabolic disease (e.g., ischemic heart disease, coronary artery disease, stroke, chronic kidney disease, diabetes mellitus), pulmonary disease, or renal disease 11. Current or recent (within past month) use of anti-hypertensive (including clonidine), lipid lowering, glucose- controlling, or prescription anti-inflammatory medications 12. Current or recent (within past month) opiates, benzodiazepine or benzodiazepine receptor agonists, or trazodone 13. Recent changes to or unstable treatment (changes within last 6 mo.) with prescription medications 14. Currently smoking or using nicotine 15. Current use of hormone therapy 16. Current heavy alcohol use, as defined as binge drinking on 5 or more days in the last month, or consuming more than 7 (women) or 14 (men) drinks per week in the last month (per NIAAA definition) 17. Current or recent (within the last 6 mo.) illicit drug use disorder as indicated by a score of 3 or greater on the Drug Abuse Screening Test (DAST-10) 18. Current or recent (within 6 mo.) pregnancy OR current or recent breastfeeding (within 3 mo.) OR children under the age of 2 years old in the home 19. Currently completing greater than 300 minutes of moderate intensity, or greater than 150 minutes of vigorous intensity physical activity, or an equal combination per week 20. Unstable housing AIM 2 Inclusion Criteria: 1. 18-29 years of age 2. SBP \<129 and DBP \<90 mmHg 3. Body Mass Index \> 18.5 kg/m2 and \<35 kg/m2 4. Willing to complete in-home sleep studies 5. \>= 3 Adverse Childhood Experiences 6. PSQI Global Score \>5 7. Sleep Efficiency Score \<90% Exclusion Criteria: 1. Currently undergoing treatment for a sleep disorder or diagnosed with restless leg syndrome, hypersomnia, parasomnia or narcolepsy, or obstructive sleep apnea 2. Currently performing overnight shift work 3. Lifetime history of any psychiatric disorder with psychotic features or bipolar disorder, currently undergoing treatment for substance-induced mood disorder 4. Endorsed suicidal ideation as indicated by a Moderate or High risk determination on the Columbia Suicide Risk Protocol 5. Diagnosed neurological disorder or illness affecting the central nervous system 6. Diagnosed acute or chronic autoimmune disease or chronic inflammatory condition 7. Current or previous cancer diagnosis 8. History of moderate or severe traumatic brain injury 9. Current or previous history of CBT-I treatment or sleep restriction or cognitive restructuring therapy for sleep 10. History of cardiometabolic disease (e.g., ischemic heart disease, coronary artery disease, stroke, chronic kidney disease, diabetes mellitus), pulmonary disease, or renal disease 11. Current or recent (within past month) use of anti-hypertensive (including clonidine), lipid lowering, glucose- controlling, or prescription anti-inflammatory medications 12. Current or recent (within past month) opiates, benzodiazepine or benzodiazepine receptor agonists, or trazodone 13. Recent changes to or unstable treatment (changes within last 6 mo.) with prescription medications 14. Currently smoking or using nicotine 15. Current use of hormone therapy 16. Current heavy alcohol use, as defined as binge drinking on 5 or more days in the last month, or consuming more than 7 (women) or 14 (men) drinks per week in the last month (per NIAAA definition) 17. Current or recent (within the last 6 mo.) illicit drug use disorder as indicated by a score of 3 or greater on the Drug Abuse Screening Test (DAST-10) 18. Current or recent (within 6 mo.) pregnancy OR current or recent breastfeeding (within 3 mo.) OR children under the age of 2 years old in the home 19. Currently completing greater than 300 minutes of moderate intensity, or greater than 150 minutes of vigorous intensity physical activity, or an equal combination per week 20. Unstable housing 21. Likely Obstructive Sleep Apnea, as indicated by an apnea-hypopnea index (AHI) \>= 15 events/hour or persistent hypoxemia, as indicated by an arterial oxygen saturation \<= 88% for \>5 minutes per night.

Contact & Investigator

Frequently Asked Questions